Our news journalists obtained a quote from the research from the European Institute of Oncology, "We also included the close margin cases defined as the presence of tumor cells at the first frozen section, but after deeper core out of retroareolar tissue were revealed free of malignancy. The incidence of LRR and NAC recurrence were reported, and the factors associated were analyzed. Of 948 NSM procedures, there were 88 false-negative, frozen-sections and 10 close margin cases. The 5-year cumulative incidence of LRR and NAC recurrence was 11.2 % (10/98 patients) and 2.4 % (2/98 patients), respectively. Analyzing the definitive results of retroareolar tissue, the 5-year cumulative incidence of LRR was 42.9 % (n = 4) for atypia, 10 % (n = 2) for lobular carcinoma in situ (LCIS), 10 % (n = 1) for close margins, 8.7 % (n = 3) for ductal carcinoma in situ (DCIS), and 0 % for invasive carcinoma. In situ carcinoma as a primary tumor was a significant predictor of NAC recurrence (P < 0.01). Despite a high reliability of frozen section, there is still a minority of false-negative results. Nevertheless, the LRR is considerably low."
According to the news editors, the research concluded: "This fact suggests the possibility of preservation of the NAC after discussion with the patient."
For more information on this research see: Risk of Locoregional Recurrence in Patients With False-Negative Frozen Section or Close Margins of Retroareolar Specimen in Nipple-Sparing Mastectomy. Annals of Surgical Oncology, 2012;19(13):4117-4123. Annals of Surgical Oncology can be contacted at: Springer, 233 Spring St, New York, NY 10013, USA. (Springer - www.springer.com; Annals of Surgical Oncology - www.springerlink.com/content/1068-9265/)
The news correspondents report that additional information may be obtained from M.C. Kneubil, European Inst Oncol, Div Radiotherapy, Milan, Italy.
Keywords for this news article include: Milan, Italy, Europe, Carcinoma in Situ, Surgical Oncology
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.